176 related articles for article (PubMed ID: 25111382)
1. Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes.
Chamberlain P; Delker S; Pagarigan B; Mahmoudi A; Jackson P; Abbasian M; Muir J; Raheja N; Cathers B
PLoS One; 2014; 9(8):e103638. PubMed ID: 25111382
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).
Ostrovskyi D; Rumpf T; Eib J; Lumbroso A; Slynko I; Klaeger S; Heinzlmeir S; Forster M; Gehringer M; Pfaffenrot E; Bauer SM; Schmidtkunz K; Wenzler S; Metzger E; Kuster B; Laufer S; Schüle R; Sippl W; Breit B; Jung M
Future Med Chem; 2016 Sep; 8(13):1537-51. PubMed ID: 27572962
[TBL] [Abstract][Full Text] [Related]
3. Lestaurtinib inhibits histone phosphorylation and androgen-dependent gene expression in prostate cancer cells.
Köhler J; Erlenkamp G; Eberlin A; Rumpf T; Slynko I; Metzger E; Schüle R; Sippl W; Jung M
PLoS One; 2012; 7(4):e34973. PubMed ID: 22532837
[TBL] [Abstract][Full Text] [Related]
4. Virtual screening of PRK1 inhibitors: ensemble docking, rescoring using binding free energy calculation and QSAR model development.
Slynko I; Scharfe M; Rumpf T; Eib J; Metzger E; Schüle R; Jung M; Sippl W
J Chem Inf Model; 2014 Jan; 54(1):138-50. PubMed ID: 24377786
[TBL] [Abstract][Full Text] [Related]
5. Binding of Janus kinase inhibitor tofacitinib with human serum albumin: multi-technique approach.
Abdelhameed AS; Alam P; Khan RH
J Biomol Struct Dyn; 2016 Sep; 34(9):2037-44. PubMed ID: 26440737
[TBL] [Abstract][Full Text] [Related]
6. Identification of an interaction between the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor with protein kinase C-related kinase (PRK) 1: implications for prostate cancer.
Turner EC; Kavanagh DJ; Mulvaney EP; McLean C; Wikström K; Reid HM; Kinsella BT
J Biol Chem; 2011 Apr; 286(17):15440-57. PubMed ID: 21357687
[TBL] [Abstract][Full Text] [Related]
7. Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state.
Williams NK; Lucet IS; Klinken SP; Ingley E; Rossjohn J
J Biol Chem; 2009 Jan; 284(1):284-291. PubMed ID: 18984583
[TBL] [Abstract][Full Text] [Related]
8.
Sophocleous G; Wood G; Owen D; Mott HR
Biomol NMR Assign; 2020 Oct; 14(2):245-250. PubMed ID: 32500230
[TBL] [Abstract][Full Text] [Related]
9. The very C-terminus of PRK1/PKN is essential for its activation by RhoA and downstream signaling.
Lim WG; Tan BJ; Zhu Y; Zhou S; Armstrong JS; Li QT; Dong Q; Chan E; Smith D; Verma C; Tan SL; Duan W
Cell Signal; 2006 Sep; 18(9):1473-81. PubMed ID: 16427251
[TBL] [Abstract][Full Text] [Related]
10. Structures of the PKC-iota kinase domain in its ATP-bound and apo forms reveal defined structures of residues 533-551 in the C-terminal tail and their roles in ATP binding.
Takimura T; Kamata K; Fukasawa K; Ohsawa H; Komatani H; Yoshizumi T; Takahashi I; Kotani H; Iwasawa Y
Acta Crystallogr D Biol Crystallogr; 2010 May; 66(Pt 5):577-83. PubMed ID: 20445233
[TBL] [Abstract][Full Text] [Related]
11. A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer.
Metzger E; Müller JM; Ferrari S; Buettner R; Schüle R
EMBO J; 2003 Jan; 22(2):270-80. PubMed ID: 12514133
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the novel cardiolipin binding regions identified on the protease and lipid activated PKC-related kinase 1.
Lin JLJ
Protein Sci; 2019 Aug; 28(8):1473-1486. PubMed ID: 31125460
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C-related kinase 1 and 2 play an essential role in thromboxane-mediated neoplastic responses in prostate cancer.
O'Sullivan AG; Mulvaney EP; Hyland PB; Kinsella BT
Oncotarget; 2015 Sep; 6(28):26437-56. PubMed ID: 26296974
[TBL] [Abstract][Full Text] [Related]
14. The last five amino acid residues at the C-terminus of PRK1/PKN is essential for full lipid responsiveness.
Lim WG; Zhu Y; Wang CH; Tan BJ; Armstrong JS; Dokland T; Yang H; Zhu YZ; Teo TS; Duan W
Cell Signal; 2005 Sep; 17(9):1084-97. PubMed ID: 15993750
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro.
Wang SP; Iwata S; Nakayamada S; Sakata K; Yamaoka K; Tanaka Y
Ann Rheum Dis; 2014 Dec; 73(12):2213-5. PubMed ID: 25157177
[No Abstract] [Full Text] [Related]
16. Identification of Highly Potent Protein Kinase C-Related Kinase 1 Inhibitors by Virtual Screening, Binding Free Energy Rescoring, and in vitro Testing.
Slynko I; Schmidtkunz K; Rumpf T; Klaeger S; Heinzlmeir S; Najar A; Metzger E; Kuster B; Schüle R; Jung M; Sippl W
ChemMedChem; 2016 Sep; 11(18):2084-94. PubMed ID: 27472906
[TBL] [Abstract][Full Text] [Related]
17. Differential binding of RhoA, RhoB, and RhoC to protein kinase C-related kinase (PRK) isoforms PRK1, PRK2, and PRK3: PRKs have the highest affinity for RhoB.
Hutchinson CL; Lowe PN; McLaughlin SH; Mott HR; Owen D
Biochemistry; 2013 Nov; 52(45):7999-8011. PubMed ID: 24128008
[TBL] [Abstract][Full Text] [Related]
18. [Research progress of JAK-3 kinase and its inhibitors].
Yin Y; Zhang TT; Zhang DY
Yao Xue Xue Bao; 2016 Oct; 51(10):1520-9. PubMed ID: 29932316
[TBL] [Abstract][Full Text] [Related]
19. Cyclic AMP analog blocks kinase activation by stabilizing inactive conformation: conformational selection highlights a new concept in allosteric inhibitor design.
Badireddy S; Yunfeng G; Ritchie M; Akamine P; Wu J; Kim CW; Taylor SS; Qingsong L; Swaminathan K; Anand GS
Mol Cell Proteomics; 2011 Mar; 10(3):M110.004390. PubMed ID: 21081668
[TBL] [Abstract][Full Text] [Related]
20. Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres.
Gehringer M; Forster M; Pfaffenrot E; Bauer SM; Laufer SA
ChemMedChem; 2014 Nov; 9(11):2516-27. PubMed ID: 25139757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
